An Oral Disease Modifying Drug For Relapsing Remitting Multiple Sclerosis Would Earn High Patient Shares In Both Europe And The United States

Main Category: Multiple Sclerosis
Article Date: 05 Feb 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States, according to surveyed U.S. and European neurologists.

The new report entitled Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs finds that a therapy's effect on disability is the attribute that most influences surveyed neurologists' prescribing decisions in relapsing-remitting multiple sclerosis. Clinical data and the opinions of interviewed thought leaders indicate that Biogen Idec/Elan's Tysabri has advantages in this attribute over Biogen Idec's Avonex, the market sales leading agent.

Decision Resources' proprietary clinical gold standard in 2008 for relapsing-remitting multiple sclerosis was Tysabri, most notably because of its superior efficacy in the three key aspects of the disease --disability progression, relapses, and lesions -- relative to other agents to treat the disease. Based on its robust efficacy, Tysabri will retain Decision Resources' gold standard status through 2017 for relapsing-remitting multiple sclerosis.

"Although Tysabri is disadvantaged by its rare incidence of life-threatening side effects, we do not expect any therapy in development for relapsing-remitting multiple sclerosis to displace it as the clinical gold standard," said Decision Resources Analyst Bethany Kiernan, Ph.D. "While some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that surveyed neurologists say are inferior when compared with Tysabri."

About the Report

Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources
http://www.decisionresources.com

• Additional
• References
• Citations